Abstract Library

#4427 Surufatinib combined with hepatic artery infusion chemotherapy (HAIC) as second-line and maintenance therapy for neuroendocrine carcinoma with liver metastases: A single-arm, open-label, single-centre phase II clinical study (SuHaNec)

Introduction: Neuroendocrine carcinoma (NEC) is rare and highly aggressive, and liver metastasis leads to worse outcomes for patients (pts) with limited treatment options and poor prognosis. Surufatinib (SUR) exhibited promising antitumour activity in neuroendocrine neoplasms.

Conference:

Presenting Author:

Authors: Wang Y, Wang J, Yang D, Yao W, Zhang N,

Keywords: neuroendocrine carcinoma, surufatinib, hepatic artery infusion chemotherapy, later-line treatment,

#4374 Efficacy and safety of immunotherapy combined with antiangiogenesis agents and temozolomide in neuroendocrine carcinoma

Introduction: Platinum-based doublet chemotherapy is the standard first-line treatment, without standard treatment for second-line or subsequent systemic therapy for recurrent or progressive advanced neuroendocrine cancer (NEC).

Conference:

Presenting Author:

Authors: Li X, Yang M, Fan Q, Song L,

Keywords: Neuroendocrine carcinoma, Immunotherapy, Antiangiogenesis agents, Temozolomide,

#4242 Sequential Everolimus and Sunitinib treatment in progressive, advanced, pancreatic NENs: Real-world data from the Belgian Group of Digestive Oncology DNET & NETwerk

Introduction: Everolimus and Sunitinib are often used consecutively for advanced, progressive, well-differentiated pancreatic neuroendocrine tumors (pNET), but to date no data on the optimal sequence is available.

Conference:

Presenting Author: Islam O

Authors: Islam O, van de Vyver G, Verslype C, Borbath I, Decaestecker J,

Keywords: pNEN, Everolimus, Sunitinib, mPFS, mOS, AEs,

#4237 Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumor pAtients (SAUNA trial) – Study protocol for a bi-national, multi-center, open-label, randomised, pragmatic clinical trial

Introduction: Advanced gastroenteropancreatic neuroendocrine tumors (GEP NET) are treated with targeted therapy or peptide receptor radionuclide therapy (PRRT) (177Lu-DOTATATE) upon progression under somatostatin analogues (SSA). SSA are continued life-long in functional NET, but the benefit of SSA continuation in non-functional NET is unclear. Due to ongoing activity of the somatostatin receptor pathway in GEP NET progressing on SSA, we hypothesize an added efficacy of SSA during second-line therapy.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Kuiper J, Borbath I, Dercksen W, Deroose C,

Keywords: somatostatin analogues, SSA, everolimus, sunitinib, peptide receptor radionuclide therapy, PRRT, quality of life, QoL, gastroenteropancreatic neuroendocrine tumor, GEP NET,

#4003 Neuroendocrine differentiation in gastric cancer: Epidemiological insights and therapeutic implications

Introduction: Gastric cancer (GC) with neuroendocrine differentiation (NED) represents a significant yet understudied subset, accounting for 10-40% of cases. The absence of tailored clinical guidelines highlights the urgent need for specialized treatment approaches.

Conference:

Presenting Author:

Authors: Huang Z, Wei J, Shen Y, Zhang J,

Keywords: Neuroendocrine Differentiation, Epidemiological, Treatment, Surufatinib,